Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$61 Mln
P/E Ratio
--
P/B Ratio
0.79
Industry P/E
--
Debt to Equity
0
ROE
-0.54 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
--
CFO
$-180.07 Mln
EBITDA
$-211.03 Mln
Net Profit
$-199.12 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Reneo Pharmaceuticals (RPHM)
| 13.13 | 26.57 | 19.87 | -74.33 | -36.92 | -- | -- |
|
BSE Sensex*
| 2.13 | 3.91 | 4.44 | 8.38 | 11.79 | 20.19 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
|
|---|---|---|
|
Reneo Pharmaceuticals (RPHM)
| -31.33 | -72.75 |
|
S&P Small-Cap 600
| 13.89 | -17.42 |
|
BSE Sensex
| 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.02 | 0.68 | -- | -- |
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and... selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California. Read more
Founder & Executive Chairman
Mr. Michael G. Grey
Founder & Executive Chairman
Mr. Michael G. Grey
Headquarters
Irvine, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Reneo Pharmaceuticals Inc (RPHM) stood at $ 80 Mln as on 30-Jun-24
The share price of Reneo Pharmaceuticals Inc (RPHM) is $1.81 (NASDAQ) as of 04-Oct-2024 18:32 EDT. Reneo Pharmaceuticals Inc (RPHM) has given a return of -36.92% in the last 3 years.
Reneo Pharmaceuticals Inc (RPHM) has a market capitalisation of $ 61 Mln as on 04-Oct-2024. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Reneo Pharmaceuticals Inc (RPHM) is 0.79 times as on 04-Oct-2024, a 64% discount to its peers’ median range of 2.20 times.
Since, TTM earnings of Reneo Pharmaceuticals Inc (RPHM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Reneo Pharmaceuticals Inc (RPHM) and enter the required number of quantities and click on buy to purchase the shares of Reneo Pharmaceuticals Inc (RPHM).
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
The CEO & director of Mr. Michael G. Grey. is Reneo Pharmaceuticals Inc (RPHM), and CFO & Sr. VP is Mr. Michael G. Grey.
There is no promoter pledging in Reneo Pharmaceuticals Inc (RPHM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
0
|
| Reneo Pharmaceuticals Inc. (RPHM) | Ratios |
|---|---|
|
Return on equity(%)
|
-68.33
|
|
Operating margin(%)
|
-4286.57
|
|
Net Margin(%)
|
-3851.29
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Reneo Pharmaceuticals Inc (RPHM) was $0 Mln.
$-15.49
(
